<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02402192</url>
  </required_header>
  <id_info>
    <org_study_id>1411-MAD-079-CB</org_study_id>
    <nct_id>NCT02402192</nct_id>
  </id_info>
  <brief_title>Type of Gonadotropin and Embryo Kinetics of Development</brief_title>
  <acronym>PEM-ESD</acronym>
  <official_title>A Prospective Randomized Trial to Analyze the Effect of the Gonadotropin Administered During Control Ovarian Stimulation on Embryo Kinetics of Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IVI Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IVI Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is proposed to determine the effect of three types of gonadotropins that are
      currently used in protocols of controlled ovarian stimulation in women undergoing in vitro
      fertilization techniques on the kinetics of embryonic development.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T5 defined as the time that embryo needs to reach a 5-cell stage.</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stimulation (days)</measure>
    <time_frame>a month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of gonadotropins (IU)</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of FSH (IU) Levels of estradiol (pg / ml) - Levels of progesterone (ng / ml) - Fertilization rate - Number of embryos transferred and cryopreserved - Pregnancy rate - Implantation</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of estradiol (pg / ml) Number of embryos transferred and cryopreserved - Pregnancy rate - Implantation</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of progesterone (ng/ml)</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred and cryopreserved</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>A monthe</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation rate per cycle initiated</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian hyperstimulation syndrome rate</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timings of cellular divisions</measure>
    <time_frame>A month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Corifollitropin alfa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HP- hMG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <arm_group_label>Corifollitropin alfa</arm_group_label>
    <arm_group_label>recombinant FSH</arm_group_label>
    <arm_group_label>HP- hMG</arm_group_label>
    <other_name>Elonva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women &lt;38 years old

          -  Weight &lt;60 kg

          -  Own oocytes

          -  Patients have to provide signed informed consent

        Exclusion Criteria:

          -  Oocyte donors

          -  Vitrified oocytes

          -  Severe male factor (&lt;1 million spz/ml)

          -  Weight &gt;60 kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmen Bou, Graduate</last_name>
    <phone>911802900</phone>
    <email>Carmen.Bou@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Cruz, PhD</last_name>
    <phone>911802900</phone>
    <email>Maria.Cruz@ivi.es</email>
  </overall_contact_backup>
  <reference>
    <citation>Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A. Embryo incubation and selection in a time-lapse monitoring system improves pregnancy outcome compared with a standard incubator: a retrospective cohort study. Fertil Steril. 2012 Dec;98(6):1481-9.e10. doi: 10.1016/j.fertnstert.2012.08.016. Epub 2012 Sep 10.</citation>
    <PMID>22975113</PMID>
  </reference>
  <results_reference>
    <citation>Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009 Dec;24(12):3063-72. doi: 10.1093/humrep/dep291. Epub 2009 Aug 14. Erratum in: Hum Reprod. 2014 May;29(5):1116-20.</citation>
    <PMID>19684043</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Velasco JA, Zúñiga A, Pacheco A, Gómez R, Simón C, Remohí J, Pellicer A. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod. 2004 Jul;19(7):1530-8. Epub 2004 May 20.</citation>
    <PMID>15155606</PMID>
  </results_reference>
  <results_reference>
    <citation>Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Muñoz M, García-Velasco JA. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013 Mar;26(3):253-9. doi: 10.1016/j.rbmo.2012.11.015. Epub 2012 Dec 5.</citation>
    <PMID>23352098</PMID>
  </results_reference>
  <results_reference>
    <citation>Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health. 2011;3:243-55. doi: 10.2147/IJWH.S15002. Epub 2011 Aug 8.</citation>
    <PMID>21892335</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcos Meseguer, Javier Herrero, Alberto Tejera,Karen Marie Hilligsoe , Niels Birger Ramsing, and Jose Remohı. The use of morphokinetics as apredictor of embryo implantation. Human Reproduction, Vol.0, No.0 pp. 1-14, 2011</citation>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2015</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IVI Madrid</investigator_affiliation>
    <investigator_full_name>Juan A Garcia-Velasco</investigator_full_name>
    <investigator_title>PhD MD</investigator_title>
  </responsible_party>
  <keyword>corifollitropin alfa</keyword>
  <keyword>recombinant FSH</keyword>
  <keyword>HP-hMG</keyword>
  <keyword>time-lapse</keyword>
  <keyword>kinetics of development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

